Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pherecydes Appoints CEO

This article was originally published in Scrip

Executive Summary

Pherecydes Pharma, a biotech developing anti-infective therapies based on lytic bacteriophages, has appointed Guy-Charles Fanneau de La Horie CEO. Fanneau de La Horie brings more than 20 years' experience to Pherecydes and has previously held various management roles including positions within Schering-Plough, Biogen and IDM. Recently he was CEO of PathoQuest and previously he held the same position at Neovacs. Prior to this, he was at Biogen where he set up and ran the subsidiaries in France and Benelux.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel